FDA Stem Cell Regulatory Oversight Based On Xenotransplantation Guidance
Executive Summary
FDA is basing its regulation of stem cell clinical trials on its xenotransplantation product guidance, Commissioner McClellan said at a Sept. 4 meeting of the President's Council on Bioethics in Washington, D.C